Reports Q3 revenue $153.6M, consensus $151.26M. “We had another solid quarter of revenue growth driven by Xenium, as we continued to ramp operations and drive exceptional demand with researchers worldwide,” said Serge Saxonov, co-founder and CEO. “Xenium’s incredibly steep adoption curve in just three full quarters of launch has put the platform on a best-in-class trajectory. The extraordinary customer enthusiasm and demand we are seeing for this platform further strengthens our conviction in the spatial opportunity and validates our multi-platform strategy and investment.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TXG:
- 10x Genomics Reports Third Quarter 2023 Financial Results
- 10x Genomics: UPC declines to issue second injunction against NanoString
- 10x Genomics price target lowered to $47 from $66 at Barclays
- Bold NanoString investors ‘hard to find’ after injunction, says Stifel
- 10x Genomics EU win may not have clear readthrough to U.S., says Canaccord